sanofi aventis could succeed in its bid for Genzime, Sanofi Aventis France
Release Date: 2011-02-16
sanofi aventis could succeed in its bid for GenzimeAccording to the Wall Street Journal , French pharmaceutical giant should finally succeed in its bid to take over American Biotech company Genzime. Genzime shareholders should receive U$74 per share, after having refused U$69 per share. At U$19 billion this is the second largest take over in the history of biotechnologies.
Although analysts estimate that the additional revenues would not compensate for the future loss of revenues due to patent expirations, this acquisitions could help sanofi aventis enter in the orphan disease market.
sanofi aventis could succeed in its bid for Genzime
According to the Wall Street Journal , French pharmaceutical giant should finally succeed in its bid to take over American Biotech company Genzime. Genzime shareholders should receive U$74 per share, after having refused U$69 per share. At U$19 billion this is the second largest take over in the history of biotechnologies.
Although analysts estimate that the additional revenues would not compensate for the future loss of revenues due to patent expirations, this acquisitions could help sanofi aventis enter in the orphan disease market.
Source: Focus Reports
| Type: | NORMAL |
| Company: | Sanofi Aventis France |
| Country: | France |